Aldeyra Therapeutics (ALDX)
(Real Time Quote from BATS)
$4.18 USD
+0.48 (12.97%)
Updated May 14, 2024 03:55 PM ET
After-Market: $4.17 -0.01 (-0.24%) 4:10 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Aldeyra Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 43 | 63 | 56 | 36 | 63 |
Income After Depreciation & Amortization | -43 | -63 | -56 | -36 | -63 |
Non-Operating Income | 7 | 2 | 0 | 0 | 2 |
Interest Expense | 2 | 2 | 2 | 2 | 1 |
Pretax Income | -38 | -62 | -58 | -38 | -62 |
Income Taxes | 0 | 0 | 0 | 0 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -38 | -62 | -58 | -38 | -61 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -38 | -62 | -58 | -38 | -61 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -62 | -56 | -36 | -63 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -43 | -63 | -56 | -36 | -63 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 58.94 | 58.41 | 54.04 | 33.97 | 27.11 |
Diluted EPS Before Non-Recurring Items | -0.64 | -1.06 | -1.07 | -1.11 | -2.05 |
Diluted Net EPS (GAAP) | -0.64 | -1.06 | -1.07 | -1.11 | -2.24 |
Fiscal Year end for Aldeyra Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 9.39 | 6.10 | 9.55 | 10.34 | 16.81 |
Income After SG&A, R&D, and Dept/Amort Expenses | -9.39 | -6.10 | -9.55 | -10.34 | -16.81 |
Non-Operating Income | 1.81 | 1.86 | 1.90 | 1.88 | 1.68 |
Interest Expense | 0.50 | 0.51 | 0.54 | 0.53 | 0.49 |
Pretax Income | -8.08 | -4.75 | -8.19 | -8.99 | -15.62 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.08 | -4.75 | -8.19 | -8.99 | -15.62 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.08 | -4.75 | -8.19 | -8.99 | -15.62 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 59.42 | 59.41 | 58.99 | 58.79 | 58.79 |
Diluted EPS Before Non-Recurring Items | -0.14 | -0.08 | -0.14 | -0.15 | -0.27 |
Diluted Net EPS (GAAP) | -0.14 | -0.08 | -0.14 | -0.15 | -0.27 |